DOI: 10.12890/2026_006253
Anasarca secondary to cytomegalovirus viremia in a post-liver transplant patient
Authors
noor.albusta@lahey.org
Keywords
Cytomegalovirus infection, liver transplantation, anasarca, ascites, immunosuppressionAbstract
Introduction: Cytomegalovirus (CMV) infection is a common complication following solid organ transplantation and is associated with significant morbidity. While CMV classically presents with systemic symptoms, bone marrow suppression or gastrointestinal disease, atypical manifestations may occur. Anasarca and refractory ascites in liver transplant recipients are more commonly attributed to graft dysfunction, vascular complications, cardiac disease or renal pathology, and CMV is not often considered as a primary aetiology.
Case description: A 63-year-old woman with a history of alcohol-related cirrhosis underwent deceased donor liver transplantation and later presented with progressive abdominal distension and bilateral lower extremity oedema. Evaluation demonstrated tense ascites and anasarca without evidence of graft dysfunction, acute rejection, portal vascular complications, cardiac disease or nephrotic syndrome. Liver function tests were normal, transthoracic echocardiography revealed preserved systolic function, and urinalysis was negative for proteinuria. Further workup identified CMV viremia, and the patient was treated with valganciclovir per infectious disease recommendations, along with supportive measures including diuresis and large-volume paracentesis. Serial monitoring demonstrated improvement in CMV viral load with corresponding gradual resolution of fluid retention.
Conclusion: This case highlights CMV viremia as an important and potentially reversible cause of anasarca in post-liver transplant patients, likely mediated by CMV-induced endothelial dysfunction. Recognition of CMV-related fluid retention is essential to avoid unnecessary invasive procedures and to guide timely antiviral therapy in immunosuppressed individuals.
References
- Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601–2614. doi: 10.1056/NEJMra064928
- Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013;13:93–106. doi:10.1111/ajt.12103
- Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant 2013;13:24–40; quiz 40. doi: 10.1111/ajt.12006
- Charlton M, Levitsky J, Aqel B, O’Grady J, Hemibach J, Rinella M, et al. International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients. Transplantation 2018;102:727–743. doi: 10.1097/TP.0000000000002147. Erratum in: Transplantation 2019;103:e37. doi: 10.1097/TP.0000000000002535
- Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011;121:1673–1680. doi: 10.1172/JCI45449
- Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012;14:633–641. doi: 10.1007/s11908-012-0292-2
- Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004;78:1390–1396. doi: 10.1097/01.tp.0000141989.22373.03
- Humar A, Michaels M. AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006;6:262–274. doi: 10.1111/j.1600-6143.2005.01207.x
- Lumbreras C, Manuel O, Len O, ten Berge IJM, Sgarabotto D, Hirsch HH, et al. Cytomegalovirus infection in solid organ transplant recipients. Clin Microbiol Infect 2014;20:19–26. doi: 10.1111/1469-0691.12594
- Singh N, Limaye AP. Infections in Solid-Organ Transplant Recipients. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 2015:3440–52. doi: 10.1016/B978-1-4557-4801-3
